In a trial of 2015 [75], HER2-directed CART-cells, were administered in 16 OST patients, most of them with HER2 expressing tumours (HER2 expression 26% or higher in 15 of the patient study population), inducing SD in 3 OST patients, that persisted for 12 weeks. Here, ERBB2 is linked to neoplasm.